The new drug is suitable for patients’ tumours with mutations or alterations in the PIK3CA, AKT1 or PTEN genes, which are found in approximately half of patients with advanced breast cancer.

Mutations in PIK3CA, AKT1, and alterations in PTEN occur frequently, affecting up to 50% of patients with advanced HR-positive breast cancer, but at the moment, genetic testing for those mutations ...

The combination was unable to improve OS in both the overall patient population and a subgroup of patients with specific tumour biomarkers, namely PIK3CA, AKT1, or PTEN. AZ was the first company ...

My goal under NIMH training grant funding is to elucidate mechanisms of AKT1 function on the physiology and behavior of genetically modified mice. AKT1 is proposed as possible node of dysfunction in ...

The pill has been approved for use in women with hormone receptor (HR)-positive HER2-negative breast cancer that has spread and has certain genetic mutations – in the PIK3CA, AKT1 or PTEN genes.